$ORMP News
Last published 2mo ago
- 2mo agoNNDMORMPDRTSLFWDNano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation CommitteeGlobeNewswireWALTHAM, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (NASDAQ:NNDM) ("Nano Dimension," "Nano," or the "Company") today announced the appointment of Nadav Kidron to its Board of
- 4mo agoLFWDORMPLifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic FinancingGlobeNewswireHUDSON, Mass. and YOKNEAM ILLIT, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of
- 4mo agoORMPOramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance SheetPR NewswireOramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a diversified operating company, today issued the...
- 4mo agoORMPOramed Pharmaceuticals to Join Russell 2000® and Russell 3000® IndexesPR NewswireOramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), announced today that it is set to join the U.S. small cap Russell 2000® and ...
- 7mo agoLFWDORMPLifeward Successfully Closes on Strategic Partnership with OramedGlobeNewswireHUDSON, Mass. and YOKNEAM ILLIT, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of
- 8mo agoLFWDORMPLifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical CompanyGlobeNewswirePositions Lifeward as a diversified biomedical innovation company with clear path to profitability Integration of Oramed's POD™ oral delivery technology expands Lifeward into biotech markets while Oramed funds
- 10mo agoLFWDORMPLifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation CompanyGlobeNewswirePositions Lifeward as a MedTech platform with a clear path to cashflow positive and long-term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intended to provide
- 10mo agoORMPLFWDOramed and Lifeward Announce Strategic TransactionPR NewswireOramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed") and Lifeward Ltd. (NASDAQ: LFWD) ("Lifeward") today announced the signing of...
- 10mo agoORMPOramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend PaymentsPR NewswireOramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) today announced it has received an $18 million payment from Scilex Holdings Inc.,...
- 11mo agoORMPOramed Reports Fiscal Third Quarter 2025 Financial ResultsPR NewswireOramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently...
- 11mo agoORMPORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTSPR NewswireThe Board of Directors of Oramed Pharmaceuticals Inc. (the "Company") announced today that it has unanimously adopted a Rights Agreement, dated...
- 1y agoORMPOramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth InitiativesPR NewswireOramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a clinical-stage pharmaceutical company, today issued a...
- 1y agoORMPDRTSOramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau MedicalPR NewswireOramed Pharmaceuticals Inc. ("Oramed" or the "Company"), (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery...
- 1y agoDRTSDRTSWORMPAlpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed PharmaceuticalsGlobeNewswireJERUSALEM, April 28, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®,
- 1y agoORMPOramed Pharmaceuticals Issues Letter to ShareholdersPR NewswireOramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug...
- 1y agoORMPOramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral InsulinPR NewswireOramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug...
- 1y agoORMPSCLXScilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and InnovationGlobeNewswirePALO ALTO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or the "Company")), an innovative revenue-generating company focused on acquiring, developing and commercializing the
- 2y agoORMPSCLXOramed Pharmaceuticals Announces Restructuring of Scilex Holding Company DebtPR NewswireOramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug...
- 2y agoORMPOramed Letter to ShareholdersPR NewswireOramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ("Oramed") (www.oramed.com), a clinical-stage pharmaceutical company focused on the...
- 2y agoORMPOramed Pharmaceuticals Inc. Announces the Buy-Back of its Common StockPR NewswireOramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (the "Company") (www.oramed.com), a clinical-stage pharmaceutical company focused on the...
- 2y agoORMPSCLXScilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and InnovationGlobeNewswirePALO ALTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex")), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain
- 2y agoORMPOramed Letter to ShareholdersPR NewswireOramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral...
- 3y agoORMPPhaseV Raises $15 Million to Push the Boundaries of ML for Clinical Trial OptimizationPR NewswirePhaseV a pioneer in causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced today that it has raised $15 ...
- 3y agoORMPOramed Announces $101,875,000 Short-Term Senior Secured Note Transaction with Scilex Holding CompanyPR Newswire18-month loan with interest rate of SOFR plus 8.5% Oramed receives warrants to purchase up to 17 million shares of Scilex common stock The Senior Secured Note with Scilex replaces Oramed's previously announced Stock
- 3y agoORMPOramed Signs Term Sheet with HTIT to Create a Joint Venture to Advance Oral Drug Delivery Technology GloballyPR NewswireJV will have global marketing rights to oral drug delivery technologyHTIT to invest $60 million, Oramed to invest $10 million into JVHTIT to provide a supply agreement for oral insulin capsule JV to advance registration
- 3y agoORMPOramed to Present at the 83rd American Diabetes Association ConferencePR NewswireNEW YORK, June 20, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), announced today that it has been selected to present an oral abstract presentation at the American Diabetes
- 3y agoORMPOramed to Present at Novel Therapies for Type 2 Diabetes & Obesity SummitPR NewswireNEW YORK, May 18, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), announced today that Chief Scientific Officer Dr. Miriam Kidron will deliver an in-person presentation at
- 3y agoORMPOramed Announces that its Chinese Partner, HTIT, has Successfully Completed a Phase 3 Oral Insulin Clinical Trial and Submitted a Marketing Authorization Application in ChinaPR NewswireOramed has completed an analysis of its U.S.-based Phase 3 oral insulin trial with significant lowering of A1C levels seen in patient subgroups NEW YORK, May 15, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc.
- 3y agoORMPOramed Pharmaceuticals Issues Shareholder UpdatePR NewswireNEW YORK, Feb. 9, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), announced today that it continues to conduct a comprehensive analysis of the data from its discontinued
- 3y agoORMPOramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 DiabetesPR NewswireNEW YORK, Jan. 11, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today top-line
- 3y agoBXBLPLLNVO+3Cramer's lighting round: Stay away from BlacklineCNBC"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
- 3y agoORMPOramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of DiabetesPR NewswireNEW YORK, Jan. 4, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today
- 3y agoORMPOramed Letter to ShareholdersPR NewswireTopline Pivotal Phase 3 Oral Insulin Data Expected Mid-January 2023Phase 2 NASH Trial Achieved Primary and Secondary EndpointsDefinitive Deal Signed to Commercialize Oral Insulin in South Korea $160 Million in Cash and
- 3y agoORMPOramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and MetabolismPR NewswireNEW YORK, Nov. 29, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today
- 3y agoORMPOramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASHPR NewswireAchieved primary endpoint of safety and tolerability in participants with Type 2 diabetes with NASH.Oral insulin candidate demonstrates consistent trends across key secondary endpoints with reduction of liver fat, liver
- 3y agoORMPOramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South KoreaPR NewswireMedicox to Distribute Oramed's Oral Insulin in South Korea, if approvedOramed to Receive Up to $18 Million in Developmental MilestonesOramed to Receive up to 15% Royalties on Gross SalesLarge Market Potential: 1 in 7
- 4y agoORMPOramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASHPR NewswireWebinar scheduled for Thursday, November 17, 2022, at 11:00 a.m. ESTFeaturing key opinion leader discussion on current treatment landscapeNEW YORK, Nov. 9, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)
- 4y agoORMPOramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 VaccinePR NewswirePrimary and secondary endpoints of safety and immunogenicity met Oral vaccine elicited a potentially protective IgG response with significant seroconversion from baseline Trial shows proof of concept for oral delivery of
- 4y agoORMPOramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin CandidatePR NewswirePrimary endpoint met: ORMD-0801 was safe and well tolerated Secondary endpoint met: ORMD-0801 showed clinically meaningful reduction of liver fat from baseline at 12 weeks Strong evidence for treatment of NASH using Oramed's oral insulin NEW YORK, S
- 4y agoORMPOramed to Present at H.C. Wainwright 24th Annual Global Investment ConferencePR NewswireNEW YORK, Sept. 6, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Office
- 4y agoORMPOramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin TrialPR Newswire- ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol - ORA-D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023 NEW YORK, July 26, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (
- 4y agoORMPOramed to Present at the Upcoming Canaccord Genuity Annual Growth ConferencePR NewswireNEW YORK, July 11, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will present an in-
- 4y agoORMPOramed Letter to ShareholdersPR Newswire$169 Million in Cash and Investments Pivotal Phase 3 Oral Insulin Data Expected January 2023 Phase 2 NASH Data Expected This Quarter Oravax - Oral Vaccine NEW YORK, July 7, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP)
- 4y agoORMPOramed Appoints Dr. Anne Peters to its Scientific Advisory BoardPR NewswireNEW YORK, June 1, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Anne Peters, MD, to its
- 4y agoORMPOramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of DiabetesPR NewswireNEW YORK, May 24, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Pat
- 4y agoORMPOramed to Present at H.C. Wainwright Global Investment ConferencePR NewswireNEW YORK, May 18, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer
- 4y agoORMPOramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1PR NewswireORMD-0801 positioned to potentially be the first FDA approved oral insulin for the treatment of diabetes Completed enrollment of 710 patients for the Phase 3 ORA-D-013-1 study Top line data expected in January 2023 NEW YORK, May 3, 2022 /PRNewsw
- 4y agoORMPOramed Granted NASH Patent in EuropePR NewswireNEW YORK, April 5, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the European Patent Office has granted the
- 4y agoORMPOramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among PhysiciansPR NewswireNEW YORK, March 29, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results from a diabetes m
- 4y agoORMPOramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 DiabetesPR NewswireNEW YORK, March 22, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that it will host a web